VJHemOnc Podcast
Key updates on CAR-T therapy for multiple myeloma
Aug 2, 2021
Nina Shah and other experts discuss the use of CAR-T therapy in multiple myeloma, highlighting the impressive results of the CRB-401 study and the significance of deep responses. They also explore the improvements in quality of life with IDESL treatment, challenges related to determining treatment lines, and the approval of the first cell-based gene therapy. The podcast covers the safety, efficacy, and ongoing studies of Sulta Cell and the use of T-cell engaging antibodies for multiple myeloma, including factors to consider when selecting therapy.
37:53
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Idocel (BB-2121) has shown promising results in trials, with FDA approval as the first cell-based gene therapy for multiple myeloma.
- Bi-specific T-cell engagers (BiTEs) offer unique advantages such as off-the-shelf availability and shorter treatment timelines for multiple myeloma patients.
Deep dives
Idocel (BB-2121) as a BCMA CAR-T cell therapy for multiple myeloma
Idocel, also known as BB-2121, is an investigational chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen (BCMA) in patients with multiple myeloma. The therapy has shown promising overall response rates and median progression-free survival in phase one and two trials. The updated data from the CRB-401 study revealed a median progression-free survival of 8.8 months and an overall survival of 34.2 months. Based on these positive results, Idocel has received FDA approval as the first cell-based gene therapy for multiple myeloma.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
